JP2002536418A - ウイルスワクチン - Google Patents

ウイルスワクチン

Info

Publication number
JP2002536418A
JP2002536418A JP2000598175A JP2000598175A JP2002536418A JP 2002536418 A JP2002536418 A JP 2002536418A JP 2000598175 A JP2000598175 A JP 2000598175A JP 2000598175 A JP2000598175 A JP 2000598175A JP 2002536418 A JP2002536418 A JP 2002536418A
Authority
JP
Japan
Prior art keywords
mixture
nucleic acid
sequence
loop
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000598175A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002536418A5 (enExample
Inventor
ミヒャエル・シュライバー
Original Assignee
シュトラトマン・アクチェンゲゼルシャフト・ウント・コムパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シュトラトマン・アクチェンゲゼルシャフト・ウント・コムパニー filed Critical シュトラトマン・アクチェンゲゼルシャフト・ウント・コムパニー
Publication of JP2002536418A publication Critical patent/JP2002536418A/ja
Publication of JP2002536418A5 publication Critical patent/JP2002536418A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2000598175A 1999-02-12 1999-12-03 ウイルスワクチン Withdrawn JP2002536418A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19907485A DE19907485B4 (de) 1999-02-12 1999-02-12 Virus-Vakzine
DE19907485.2 1999-02-12
PCT/EP1999/009759 WO2000047223A2 (de) 1999-02-12 1999-12-03 Virus-vakzine

Publications (2)

Publication Number Publication Date
JP2002536418A true JP2002536418A (ja) 2002-10-29
JP2002536418A5 JP2002536418A5 (enExample) 2006-10-26

Family

ID=7898389

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000598175A Withdrawn JP2002536418A (ja) 1999-02-12 1999-12-03 ウイルスワクチン

Country Status (12)

Country Link
US (1) US20060222665A1 (enExample)
EP (1) EP1149167B1 (enExample)
JP (1) JP2002536418A (enExample)
CN (1) CN1268748C (enExample)
AT (1) ATE260978T1 (enExample)
AU (1) AU1976100A (enExample)
DE (2) DE19907485B4 (enExample)
DK (1) DK1149167T3 (enExample)
ES (1) ES2216619T3 (enExample)
PT (1) PT1149167E (enExample)
WO (1) WO2000047223A2 (enExample)
ZA (1) ZA200106155B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7118874B2 (en) * 1998-10-09 2006-10-10 Variation Biotechnologies Inc. Immunogenic formulation and process for preparation thereof
EP1311278A4 (en) * 2000-08-07 2005-01-05 Sloan Kettering Institutefor C METHOD AND IMMUNIZATION COMPOSITION USING MIXED POOLS OF NUCLEIC ACIDS OR MUTED PEPTIDES
DE10218129A1 (de) * 2002-04-23 2003-11-20 Univ Ruprecht Karls Heidelberg Genetischer Impfstoff gegen RNA-Virus-Infektionen
BRPI0504117A (pt) * 2005-09-05 2007-05-22 Fundacao De Amparo A Pesquisa epìtopos, combinação de epìtopos, usos de epìtopos ou sua combinação, composição, usos da composição, vacinas profiláticas anti-hiv-1, vacinas terapêuticas, método para a identificação de epìtopos e métodos para o tratamento ou prevenção
DK2170384T3 (en) 2007-07-02 2016-07-25 Etubics Corp METHODS AND COMPOSITIONS FOR THE PRODUCTION OF AN adenovirus vector for use in higher vaccination
CN101591379B (zh) * 2008-05-27 2017-01-18 中国疾病预防控制中心性病艾滋病预防控制中心 基于eiav减毒活疫苗的氨基酸突变而构建的抗hiv疫苗
CN103865945A (zh) * 2010-02-10 2014-06-18 中国人民解放军军事医学科学院放射与辐射医学研究所 Tat核心肽段在制备高效、可溶性表达的外源蛋白中的应用
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
US10245313B2 (en) * 2014-10-24 2019-04-02 Versitech Limited DNA motif compounds and methods for inducing specific antibodies and cellular immunity
WO2016187151A1 (en) * 2015-05-18 2016-11-24 Calimmune, Inc. Methods of discriminating between hiv-1 and lentiviral vectors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89118A0 (en) * 1988-02-03 1989-08-15 Microgenesys Inc Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
US5851813A (en) * 1990-07-12 1998-12-22 President And Fellows Of Harvard College Primate lentivirus antigenic compositions
FR2677363A1 (fr) * 1991-06-07 1992-12-11 Pasteur Institut Compositions a base de peptides multiepitopiques, leur procede d'obtention et leurs applications, notamment en tant que vaccins.
WO1994022917A1 (en) * 1993-04-05 1994-10-13 University Of Massachusetts Medical Center Cross-reactive influenza a immunization
AU6829494A (en) * 1993-08-02 1995-02-28 Chiron Corporation Recombinant constructs using replacement sequences in hypervariable regions
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses

Also Published As

Publication number Publication date
ES2216619T3 (es) 2004-10-16
DE59908783D1 (de) 2004-04-08
AU1976100A (en) 2000-08-29
EP1149167A2 (de) 2001-10-31
US20060222665A1 (en) 2006-10-05
PT1149167E (pt) 2004-07-30
CN1268748C (zh) 2006-08-09
EP1149167B1 (de) 2004-03-03
ZA200106155B (en) 2002-08-05
DK1149167T3 (da) 2004-07-12
DE19907485B4 (de) 2008-01-17
DE19907485A1 (de) 2000-09-28
WO2000047223A2 (de) 2000-08-17
WO2000047223A3 (de) 2000-11-16
CN1348496A (zh) 2002-05-08
ATE260978T1 (de) 2004-03-15

Similar Documents

Publication Publication Date Title
JP7443608B2 (ja) ＳＡＲＳ－ＣＯＶ－２ ｍＲＮＡドメインワクチン
US20240100151A1 (en) Variant strain-based coronavirus vaccines
US20240293534A1 (en) Coronavirus glycosylation variant vaccines
US20250367278A1 (en) Variant strain-based coronavirus vaccines
US20240207392A1 (en) Epstein-barr virus mrna vaccines
US20230355743A1 (en) Multi-proline-substituted coronavirus spike protein vaccines
US20220323572A1 (en) Coronavirus rna vaccines
WO2022221440A1 (en) Influenza-coronavirus combination vaccines
WO2023092069A1 (en) Sars-cov-2 mrna domain vaccines and methods of use
CA3168902A1 (en) Coronavirus rna vaccines
WO2022266010A1 (en) Mrna vaccines encoding flexible coronavirus spike proteins
JP2002536418A (ja) ウイルスワクチン
EP2021356B1 (en) Hiv vaccine
US20040115621A1 (en) Ancestral viruses and vaccines
KR100542547B1 (ko) 한국인에서 분리된 ｈｉｖ-1 아형 ｂ의 재조합 클론 및 그제조방법
US20040116684A1 (en) Ancestral viruses and vaccines

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060907

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060907

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20081002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20081002